The prognostic role of an optimal machine learning model based on clinical available indicators in HCC patients

被引:1
|
作者
Lou, Xiaoying [1 ]
Ma, Shaohui [1 ]
Ma, Mingyuan [2 ]
Wu, Yue [1 ]
Xuan, Chengmei [1 ]
Sun, Yan [3 ]
Liang, Yue [3 ]
Wang, Zongdan [1 ]
Gao, Hongjun [1 ,3 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China
[2] Univ Calif Berkeley, Dept Stat, Dept Elect Engn & Comp Sci, Berkeley, CA USA
[3] Chinese Acad Med Sci, Shanxi Med Univ, Shanxi Prov Canc Hosp, Shanxi Hosp,Canc Hosp,Dept Clin Lab, Taiyuan, Shanxi, Peoples R China
关键词
hepatocellular carcinoma (HCC); overall survival (OS); OS-related clinical characteristic (OCC) panel; progression-free survival (PFS); random survival forests (RSF); GAMMA-GLUTAMYL-TRANSFERASE; NEURAL-NETWORK MODEL; LONG-TERM SURVIVAL; HEPATOCELLULAR-CARCINOMA; LACTATE-DEHYDROGENASE; ALKALINE-PHOSPHATASE; RECURRENCE; LIVER; HEPATECTOMY; RESECTION;
D O I
10.3389/fmed.2024.1431578
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although methods in diagnosis and therapy of hepatocellular carcinoma (HCC) have made significant progress in the past decades, the overall survival (OS) of liver cancer is still disappointing. Machine learning models have several advantages over traditional cox models in prognostic prediction. This study aimed at designing an optimal panel and constructing an optimal machine learning model in predicting prognosis for HCC. A total of 941 HCC patients with completed survival data and preoperative clinical chemistry and immunology indicators from two medical centers were included. The OCC panel was designed by univariate and multivariate cox regression analysis. Subsequently, cox model and machine-learning models were established and assessed for predicting OS and PFS in discovery cohort and internal validation cohort. The best OCC model was validated in the external validation cohort and analyzed in different subgroups. In discovery, internal and external validation cohort, C-indexes of our optimal OCC model were 0.871 (95% CI, 0.863-0.878), 0.692 (95% CI, 0.667-0.717) and 0.648 (95% CI, 0.630-0.667), respectively; the 2-year AUCs of OCC model were 0.939 (95% CI, 0.920-0.959), 0.738 (95% CI, 0.667-0.809) and 0.725 (95% CI, 0.643-0.808), respectively. For subgroup analysis of HCC patients with HBV, aged less than 65, cirrhosis or resection as first therapy, C-indexes of our optimal OCC model were 0.772 (95% CI, 0.752-0.792), 0.769 (95% CI, 0.750-0.789), 0.855 (95% CI, 0.846-0.864) and 0.760 (95% CI, 0.741-0.778), respectively. In general, the optimal OCC model based on RSF algorithm shows prognostic guidance value in HCC patients undergoing individualized treatment.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Learner Performance Prediction Indicators based on Machine Learning
    Sehaba, Karim
    PROCEEDINGS OF THE 12TH INTERNATIONAL CONFERENCE ON COMPUTER SUPPORTED EDUCATION (CSEDU), VOL 1, 2020, : 47 - 57
  • [42] A study of machine learning to predict NRDS severity based on lung ultrasound score and clinical indicators
    Huang, Chunyan
    Ha, Xiaoming
    Cui, Yanfang
    Zhang, Hongxia
    FRONTIERS IN MEDICINE, 2024, 11
  • [43] Publicly available machine learning models for identifying opioid misuse from the clinical notes of hospitalized patients
    Sharma, Brihat
    Dligach, Dmitriy
    Swope, Kristin
    Salisbury-Afshar, Elizabeth
    Karnik, Niranjan S.
    Joyce, Cara
    Afshar, Majid
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2020, 20 (01)
  • [44] Publicly available machine learning models for identifying opioid misuse from the clinical notes of hospitalized patients
    Brihat Sharma
    Dmitriy Dligach
    Kristin Swope
    Elizabeth Salisbury-Afshar
    Niranjan S. Karnik
    Cara Joyce
    Majid Afshar
    BMC Medical Informatics and Decision Making, 20
  • [45] Predicting prognosis in COVID-19 patients using machine learning and readily available clinical data
    Campbell, Thomas W.
    Wilson, Melissa P.
    Roder, Heinrich
    MaWhinney, Samantha
    Georgantas, Robert W.
    Maguire, Laura K.
    Roder, Joanna
    Erlandson, Kristine M.
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2021, 155
  • [46] Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information
    Mcteer, Matthew
    Applegate, Douglas
    Mesenbrink, Peter
    Ratziu, Vlad
    Schattenberg, Joern M.
    Bugianesi, Elisabetta
    Geier, Andreas
    Romero Gomez, Manuel
    Dufour, Jean-Francois
    Ekstedt, Mattias
    Francque, Sven
    Yki-Jarvinen, Hannele
    Allison, Michael
    Valenti, Luca
    Miele, Luca
    Pavlides, Michael
    Cobbold, Jeremy
    Papatheodoridis, Georgios
    Holleboom, Adriaan G.
    Tiniakos, Dina
    Brass, Clifford
    Anstee, Quentin M.
    Missier, Paolo
    PLOS ONE, 2024, 19 (02):
  • [47] Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model
    Lu, Tzu-Pin
    Kuo, Kuan-Ting
    Chen, Ching-Hsuan
    Chang, Ming-Cheng
    Lin, Hsiu-Ping
    Hu, Yu-Hao
    Chiang, Ying-Cheng
    Cheng, Wen-Fang
    Chen, Chi-An
    CANCERS, 2019, 11 (02)
  • [48] Two prognostic indicators of the publication rate of clinical studies were available during ethical review
    de Jong, Jean Philippe
    Ter Riet, Gerben
    Willems, Dick Ludolf
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2010, 63 (12) : 1342 - 1350
  • [49] Model for predicting drug resistance based on the clinical profile of tuberculosis patients using machine learning techniques
    Falcao, Igor Wenner Silva
    Cardoso, Diego Lisboa
    dos Santos Santos, Albert Einstein Coutinho
    Paixao, Erminio
    Costa, Fernando Augusto R.
    Figueiredo, Karla
    Carneiro, Saul
    da Rocha Seruffo, Marcos César
    PeerJ Computer Science, 2024, 10
  • [50] A machine learning prediction model for cancer risk in patients with type 2 diabetes based on clinical tests
    Qiu, Bin
    Chen, Hang
    Zhang, Enke
    Ma, Fuchun
    An, Gaili
    Zong, Yuan
    Shang, Liang
    Zhang, Yulian
    Zhu, Huolan
    TECHNOLOGY AND HEALTH CARE, 2024, 32 (03) : 1431 - 1443